Article
JAK-ing up the Response to KIT Inhibition.
The Journal of investigative dermatology - 1 Jan 2018
Yang Jessica, Komatsubara Kimberly M, Carvajal Richard D
Abstract excerpt
Only a subset of patients with KIT-mutant melanoma derives clinical benefit from KIT inhibition, and the development of resistance is common. Efforts to improve the efficacy of KIT inhibition are limited by a lack of understanding of the mechanisms underlying response and resistance to treatment. Findings from Delyon et al. suggest that signal transducer and activator of transcription 3 activation may be an...
Topics
- Humans
- Melanoma
- Mutation
- Proto-Oncogene Proteins c-kit
- Pyrimidines
- STAT3 Transcription Factor
- Skin Neoplasms